[go: up one dir, main page]

NZ733896B2 - Anti-transthyretin antibodies - Google Patents

Anti-transthyretin antibodies Download PDF

Info

Publication number
NZ733896B2
NZ733896B2 NZ733896A NZ73389616A NZ733896B2 NZ 733896 B2 NZ733896 B2 NZ 733896B2 NZ 733896 A NZ733896 A NZ 733896A NZ 73389616 A NZ73389616 A NZ 73389616A NZ 733896 B2 NZ733896 B2 NZ 733896B2
Authority
NZ
New Zealand
Prior art keywords
ttr
antibodies
transthyretin
accumulation
chain cdrs
Prior art date
Application number
NZ733896A
Other versions
NZ733896A (en
Inventor
Avijit Chakrabartty
Jeffrey N Higaki
Yue Liu
Tarlochan S Nijjar
Original Assignee
Novo Nordisk A/S
University Health Network
Filing date
Publication date
Application filed by Novo Nordisk A/S, University Health Network filed Critical Novo Nordisk A/S
Priority claimed from PCT/IB2016/050415 external-priority patent/WO2016120810A1/en
Publication of NZ733896A publication Critical patent/NZ733896A/en
Publication of NZ733896B2 publication Critical patent/NZ733896B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

Claims (1)

1. SUMMARY OF THE CLAIMED INVENTION The invention provides antibodies that bind to transthyretin and comprise three heavy chain CDRs and three light chain CDRs substantially from antibody 14G8. Some antibodies comprise three Kabat heavy chain CDRs and three Kabat light chain CDRs of the antibody
NZ733896A 2016-01-28 Anti-transthyretin antibodies NZ733896B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562109002P 2015-01-28 2015-01-28
US201562266556P 2015-12-11 2015-12-11
PCT/IB2016/050415 WO2016120810A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Publications (2)

Publication Number Publication Date
NZ733896A NZ733896A (en) 2024-11-29
NZ733896B2 true NZ733896B2 (en) 2025-03-04

Family

ID=

Similar Documents

Publication Publication Date Title
WO2018007923A3 (en) Anti-transthyretin antibodies
WO2018007924A3 (en) Anti-transthyretin antibodies
WO2018007922A3 (en) Anti-transthyretin antibodies
SA517381981B1 (en) Anti-transthyretin antibodies
PH12017501318B1 (en) Anti-transthyretin antibodies
MX2020003041A (en) Anti-transthyretin antibodies.
SA517381991B1 (en) Anti-Transthyretin Antibodies
EA201990594A1 (en) ANTI-TIM-3 ANTIBODIES AND THEIR APPLICATION
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
CO2018004532A2 (en) Human anti-cd19 antibodies with high affinity
WO2017156500A8 (en) TGFβ1-BINDING IMMUNOGLOBULINS AND USE THEREOF
WO2015106080A3 (en) Antibodies directed against interleukin-33 (il-33)
WO2014186622A3 (en) Methods of treatment for guillain-barre syndrome
WO2017120523A3 (en) Anti-pro/latent myostatin antibodies and methods of use thereof
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
EA202192130A1 (en) LTBP-SPECIFIC TGF INHIBITORS AND THEIR APPLICATIONS
PH12021553109A1 (en) Humanized antibody molecules to cd138 and uses thereof
MX2016008794A (en) E. coli specific antibody sequences.
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2016007212A (en) Antibodies directed against the lukgh (lukab) toxin of staphylococcus aureus and antibody sequences.
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
NZ733896B2 (en) Anti-transthyretin antibodies
WO2015116569A3 (en) Antibodies directed against discoidin domain receptor family, member 1 (ddr1)
HK1240249A1 (en) Anti-transthyretin antibodies